See the DrugPatentWatch profile for ocrevus

Yes, there are active patents protecting Ocrevus (generic name: ocrelizumab), a prescription medication used to treat certain types of multiple sclerosis (MS) and primary progressive MS. Ocrevus is a product of Genentech, a member of the Roche Group.

According to DrugPatentWatch.com [1], an independent and reputable source for drug patents, Ocrevus has several active patents. Specifically, there are patents protecting the drug's composition, method of use, and manufacturing processes. These patents, granted by the United States Patent and Trademark Office (USPTO), extend through 2030.

It is important to note that drug patents are subject to various factors, including potential legal challenges and the drug's market performance. Consequently, the patent landscape for Ocrevus may change over time.

Sources:
[1] DrugPatentWatch.com. (n.d.). Ocrevus (ocrelizumab) Drug Patent Information. Retrieved from https://www.drugpatentwatch.com/Drug/Ocrevus.html